Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors

Brown, Sook Kwan; Tseng, Yeu-Yang; Aziz, Ammar; Baz, Mariana; Barr, Ian G.

doi:10.1016/j.antiviral.2022.105280

Cited by 5 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This substitution has been shown to reduce the oseltamivir active site hydrophobicity but increase resistance to oseltamivir when it co‐occurred with the mutation E119V in A/H3N2 viruses 52 . No NAI‐resistance markers were found in B/Victoria‐lineage viruses, which is consistent with the low frequency (<1%) of the resistant mutations in IBVs reported globally 53 …”

Section: Discussionsupporting

confidence: 73%

“… 52 No NAI‐resistance markers were found in B/Victoria‐lineage viruses, which is consistent with the low frequency (<1%) of the resistant mutations in IBVs reported globally. 53 …”

Section: Discussionmentioning

confidence: 99%

“…52 No NAI-resistance markers were found in B/Victoria-lineage viruses, which is consistent with the low frequency (<1%) of the resistant mutations in IBVs reported globally. 53 Baloxavir marboxil (Xofluza), a cap-dependent endonuclease inhibitor, has been approved for the treatment of uncomplicated influenza in Australian patients aged 12 and over. 54 However, during the 2018-2019 influenza season in Japan, the mutation I38T identified in 2.3% of A/H1N1pdm09 viruses and 8% of A/H3N2 viruses 55 was shown to reduce susceptibility to baloxavir marboxil.…”

Section: Genotypic Antiviral Drug Susceptibilitymentioning

confidence: 99%

See 2 more Smart Citations

Genome characterization of influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high‐throughput whole genome sequencing

Wang,

Kim,

Walker

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

BackgroundDuring the 2019 severe influenza season, New South Wales (NSW) experienced the highest number of cases in Australia. This study retrospectively investigated the genetic characteristics of influenza viruses circulating in NSW in 2019 and identified genetic markers related to antiviral resistance and potential virulence.MethodsThe complete genomes of influenza A and B viruses were amplified using reverse transcription‐polymerase chain reaction (PCR) and sequenced with an Illumina MiSeq platform.ResultsWhen comparing the sequencing data with the vaccine strains and reference sequences, the phylogenetic analysis revealed that most NSW A/H3N2 viruses (n = 68; 94%) belonged to 3C.2a1b and a minority (n = 4; 6%) belonged to 3C.3a. These viruses all diverged from the vaccine strain A/Switzerland/8060/2017. All A/H1N1pdm09 viruses (n = 20) showed genetic dissimilarity from vaccine strain A/Michigan/45/2015, with subclades 6B.1A.5 and 6B.1A.2 identified. All B/Victoria‐lineage viruses (n = 21) aligned with clade V1A.3, presenting triple amino acid deletions at positions 162–164 in the hemagglutinin protein, significantly diverging from the vaccine strain B/Colorado/06/2017. Multiple amino acid substitutions were also found in the internal proteins of influenza viruses, some of which have been previously reported in hospitalized influenza patients in Thailand. Notably, the oseltamivir‐resistant marker H275Y was present in one immunocompromised patient infected with A/H1N1pdm09 and the resistance‐related mutation I222V was detected in another A/H3N2‐infected patient.ConclusionsConsidering antigenic drift and the constant evolution of circulating A and B strains, we believe continuous monitoring of influenza viruses in NSW via the high‐throughput sequencing approach provides timely and pivotal information for both public health surveillance and clinical treatment.

show abstract

Section: Discussionsupporting

confidence: 73%

“… 52 No NAI‐resistance markers were found in B/Victoria‐lineage viruses, which is consistent with the low frequency (<1%) of the resistant mutations in IBVs reported globally. 53 …”

Section: Discussionmentioning

confidence: 99%

Section: Genotypic Antiviral Drug Susceptibilitymentioning

confidence: 99%

See 1 more Smart Citation

Genome characterization of influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high‐throughput whole genome sequencing

Wang,

Kim,

Walker

et al. 2024

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…A combination of T146P with a second mutation at N169S results in a further decline in the effectiveness of neuraminidase inhibitors. NA mutations H101L, A200T, D432G, H439P, and H439R also proved to decrease the effectiveness of neuraminidase inhibitors [ 40 , 47 , 48 , 49 , 50 ].…”

Section: Treatment Options and Emerging Limitations In The Treatment ...mentioning

confidence: 99%

“…They included T146P and the N169S mutation (in influenza B/Malaysia/RP2134/2019), resulting in an approximately 684-fold IC 50 increase. The D197E mutation in the IBV conferred a 15-fold growth in laninamivir IC 50 [ 45 , 48 , 50 , 73 , 74 ].…”

Section: Treatment Options and Emerging Limitations In The Treatment ...mentioning

confidence: 99%

Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects

Smyk

Szydłowska

Szulc

et al. 2022

IJMS

View full text Add to dashboard Cite

Viral evolution refers to the genetic changes that a virus accumulates during its lifetime which can arise from adaptations in response to environmental changes or the immune response of the host. Influenza A virus is one of the most rapidly evolving microorganisms. Its genetic instability may lead to large changes in its biological properties, including changes in virulence, adaptation to new hosts, and even the emergence of infectious diseases with a previously unknown clinical course. Genetic variability makes it difficult to implement effective prophylactic programs, such as vaccinations, and may be responsible for resistance to antiviral drugs. The aim of the review was to describe the consequences of the variability of influenza viruses, mutations, and recombination, which allow viruses to overcome species barriers, causing epidemics and pandemics. Another consequence of influenza virus evolution is the risk of the resistance to antiviral drugs. Thus far, one class of drugs, M2 protein inhibitors, has been excluded from use because of mutations in strains isolated in many regions of the world from humans and animals. Therefore, the effectiveness of anti-influenza drugs should be continuously monitored in reference centers representing particular regions of the world as a part of epidemiological surveillance.

show abstract

New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses

Gao,

Pascua,

Nguyen

et al. 2023

Antiviral Research

View full text Add to dashboard Cite

Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors

Cited by 5 publications

References 40 publications

Genome characterization of influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high‐throughput whole genome sequencing

Genome characterization of influenza A and B viruses in New South Wales, Australia, in 2019: A retrospective study using high‐throughput whole genome sequencing

Evolution of Influenza Viruses—Drug Resistance, Treatment Options, and Prospects

New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses

Contact Info

Product

Resources

About